UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
|-------------------------------------------------------------|-------------------------------|---------------------------|---------------------|------------------|--|
| 10/555,712 | 11/03/2005 | Herman Augustinus De Kock | TIP-0072USPCT | 2964 | |
| ²⁷⁷⁷⁷ PHILIP S. JOH | 7590 09/17/200 NSON | 8 | EXAMINER | | |
| JOHNSON & JOHNSON | | | KADAMBI, GEETA | | |
| ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003 | | | ART UNIT | PAPER NUMBER | |
| | | | 1614 | | |
| | | | | | |
| | | | MAIL DATE | DELIVERY MODE | |
| | | | 09/17/2008 | PAPER | |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | Application No. | Applicant(s) | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|--------|--|--|--|
| Office Action Comments | 10/555,712 | DE KOCK ET AL. | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| | GEETA KADAMBI | 1614 | | | | |
| The MAILING DATE of this communication app Period for Reply | ears on the cover sheet with the c | orrespondence add | ress | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). | ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI | N. nely filed the mailing date of this com D (35 U.S.C. § 133). | , | | | |
| Status | | | | | | |
| 1) Responsive to communication(s) filed on | _• | | | | | |
| | | | | | | |
| 3) Since this application is in condition for allowan | | | | | | |
| closed in accordance with the practice under E | x parte Quayle, 1935 C.D. 11, 45 | i3 O.G. 213. | | | | |
| Disposition of Claims | | | | | | |
| 4)⊠ Claim(s) <u>1-23 , 26-31</u> is/are pending in the appl | lication. | | | | | |
| 4a) Of the above claim(s) is/are withdraw | | | | | | |
| 5) Claim(s) is/are allowed. | | | | | | |
| 6) Claim(s) is/are rejected. | | | | | | |
| 7) Claim(s) is/are objected to. | | | | | | |
| 8) Claim(s) 1-23 and 26-31 are subject to restriction | on and/or election requirement. | | | | | |
| Application Papers | | | | | | |
| <u> </u> | | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | | |
| 10) The drawing(s) filed on is/are: a) acce | | | | | | |
| Applicant may not request that any objection to the o | = : : | • • | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). | | | | | | |
| 11)☐ The oath or declaration is objected to by the Ex | aminer. Note the attached Office | Action or form PTC |)-152. | | | |
| Priority under 35 U.S.C. § 119 | | | | | | |
| 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of | s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)). | on No ed in this National S | itage | | | |
| Attachment(s) | _ | | | | | |
| 1) Notice of References Cited (PTO-892) | 4) Interview Summary | | | | | |
| 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) | Paper No(s)/Mail Da 5) Notice of Informal P | | | | | |
| Paper No(s)/Mail Date | 6) Other: | | | | | |
| | | | | | | |

DETAILED ACTION

Claims 1-23 and 26-31 are pending.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 26, drawn to method of preventing. <u>Further election of species requirement 1 as set forth below is required upon electing this invention.</u>

Group II, claim(s) 28-31, drawn to method of modulating and producing. <u>Further election of species requirement 1 as set forth below is required upon electing this invention.</u>

Group III, claim(s) 1-23, 27, drawn to a compound formula (I). <u>Further election of species requirement 1 as set forth below is required upon electing this invention.</u>

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. An international application should relate to only one invention or, if there is more than one invention, the inclusion of those inventions in one international application is only permitted if all inventions are so linked as to form a single general inventive concept (PCT Rule 13.1). With respect to a group of inventions claimed in an international application, unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical

features. The claims herein lack unity of invention under PCT rule 13.1 and 13.2 since, under 37 CFR 1.475(a).

Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

The inventions listed as Groups I, II and III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I is the active ingredient of compound formula (I).

The special technical feature of Group I is method of preventing a disease with the compound formula (I), administering an effective amount of a compound of formula (I). This involves the steps of restoration of a normal physiological state and removal of the causative agent. These steps are dependent on several factors such as identification of the causative agent (for e.g. metabolic factors or environmental factors or microorganisms), the role played by the diseased animal (for e.g. capacity for tissue proliferation, defense and detoxification mechanisms which remove the causative agent) etc. Additionally method of preventing will also require diagnosis, dosage determination, route of administration and further monitoring of the treated patient. The special technical feature of Group II is the process of producing or modulating the compound of formula (I) by coupling with a peptide which involves the steps of sourcing

raw materials, optimizing reaction conditions with the final outcome of preparing the composition. The special technical feature of Group III is the active ingredients of compound formula (I).

Accordingly there is no same or corresponding special technical feature unifying Groups I, II and III and thereby lacks unity.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Election of species requirement I

If the Applicant elects Group I, II or III then they are further required to elect a single disclosed specie of compound formula (I) from claims 1-23, for example:

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims

Application/Control Number: 10/555,712

Art Unit: 1614

are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic to the above specie options: 1-23 and 26-31.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The species are structurally divergent, differ in their physical, chemical and biological properties and activities and thereby require searching in different class/subclasses and use of different search queries.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise

require all the limitations of the allowable product claim will be considered for rejoinder.

<u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to GEETA KADAMBI whose telephone number is (571)270-5234. The examiner can normally be reached on 8 am - 5 pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on 571-272-0718. The fax phone

Application/Control Number: 10/555,712 Page 7

Art Unit: 1614

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

GEETA KADAMBI Examiner Art Unit 1614

/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614